Identification of new biomarkers for clinical trials of Hsp90 inhibitors

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1256-1264

  Zhang, Hong ^a   Chung, Daun ^a   Yang, Yong Ching ^a   Neely, Laura ^a   Tsurumoto, Steven ^a   Fan, Junhua ^a   Zhang, Lin ^a   Biamonte, Marco ^a   Brekken, John ^a   Lundgren, Karen ^a   Burrows, Francis ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; CF 237; EC 69; EC 97; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RIFABUTIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745086222     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0537     Document Type: Article

References (30)

1. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15: 419-24.
2. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Mad 2004;82:488-99.
3. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
4. Gelmon KA, Eisenhauer EA, Harris AL, Retain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91: 1281-7.
5. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2: 131-8.
6. Bhat RV, Engber TM, Zhu Y, Miller MS, Contreras PC. Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice. J Pharmacol Exp Ther 1997;281: 522-30.
7. Logan A, Gonzalez AM, Hill DJ, et al. Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGF-bincling protein-2 in the adult rat brain. Endocrinology 1994;135: 2255-64.
8. Chatterjee S, Park ES, Soloff MS. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 2004;11:876-84.
9. Fottner C, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 2004;36:397-405.
10. Hirano S, Ito N, Takahashi S, Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol 2004;25:187-91.
11. Wang H, Shen SS, Diwan AH, et al. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions. J Cutan Pathol 2003;30: 599-605.
12. Dubois V, Couissi D, Schonne E, Remacle C, Trouet A. Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium. Eur J Biochem 1995; 232:47-53.
13. Maxwell P, van den Berg HW. Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett 1999;139:121-7.
14. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20.
15. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201.
16. Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004;5:105-16.
17. Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/ c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7:2703-11.
18. Sandri MT, Johansson H, Colleoni M, et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anti-cancer Res 2004;24:1261-6.
19. Dragovich T, Gordon M, Saif W, et al. Phase I study of CNF1010 (lipid formulation of 17-AAG). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia Nov. 14-18, 2005;Abstract C75.
20. Biamonte MA, Shi J, Hong K, et al. Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem 2006;49:817-28.
21. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel climeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11: 3889-96.
22. Baron-Hay S, Boyle,F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004;10:1796-806.
23. Krassas GE, Pontikides N, Kaltsas T, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88:132-5.
24. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer: present and future. Curr Cancer Drug Targets 2003;3:385-90.
25. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
26. Basso AD, Solit DB, Chiosis G, et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277: 39858-66.
27. Young JC, Barral JM, Ulrich Hartl F. More than folding: localized functions of cytosolic chaperones. Trends Biochem Sci 2003;28:541-7.
28. Hunter-Lavin C, Davies EL, Bacelar MM, et al. Hsp70 release from peripheral blood mononuclear cells. Biochem Biophys Res Commun 2004; 324:511-7.
29. Pockley AG, Shepherd J, Corton JM. Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. Immunol Invest 1998;27:367-77.
30. Zhong L, Pang X, Hidalgo GE, et al. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 2003; 27:285-90.